Agios Gets $200m Up Front In New Celgene Deal, Regains AG-120 Rights

Agios Pharmaceuticals Inc. will get $200m to kick off a new partnership with longtime collaborator Celgene Corp. under a complex agreement to develop therapies that alter the metabolic state of immune cells to enhance the immune response to cancer.